Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

PDL Forecasts $125M in Q2

By R&D Editors | June 14, 2012

INCLINE VILLAGE, Nev. (AP) – PDL BioPharma Inc. said it expects about $125 million in revenue in the second quarter on greater payments from sales of the breast cancer drug Herceptin, the eye drug Lucentis, and the multiple sclerosis drug Tysabri.

The company said royalty revenue increased about 2% compared to the second quarter of 2011, when it reported $122.1 million in royalty revenue. PDL helped develop several drugs marketed by Genentech, a unit of the Swiss pharmaceutical company Roche AG. It also helped develop Tysabri, which is marketed by Biogen Idec Inc. and Elan Corp. PLC. Its revenue in the second quarter is based on sales Genentech and Elan made in the first quarter.
The revenue estimate does not include a payment PDL makes to Novartis AG on Lucentis sales.

Analysts expected PDL to report $129.6 million in second-quarter revenue, according to FactSet.

PDL said Herceptin sales grew 4% in the first quarter. The drug is used to treat a type of breast cancer that overproduces a particular protein, and PDL said Roche attributed the improvement in sales to increased use of genetic testing for breast cancer, as well as better-quality testing. It also cited greater use of Herceptin in developing countries, including Latin America and Asia-Pacific region countries, and greater use of the drug as a treatment for stomach cancer.

Sales of Lucentis climbed 15% after the drug won additional marketing approvals in the U.S. and Europe. Sales of the cancer drug Avastin declined 1% after the Food and Drug Administration revoked its approval as a treatment for breast cancer. Sales of the asthma drug Xolair also improved.

PDL said first-quarter sales of Tysabri grew 13%.

Date: June 10, 2012
Source: Associated Press

Related Articles Read More >

2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE